Flavonoids
|
Quercetin |
Allium cepa (onions), Malus domestica (apples) |
Inhibits xanthine oxidase (XOD) and reduces inflammatory markers (IL-1β, NLRP3). |
Lowers uric acid levels, IC50 of 2.74 µmol/L for XOD inhibition, a potential treatment for HUA. |
|
Kaempferol |
Brassica oleracea (kale), Ginkgo biloba
|
It inhibits XOD and regulates uric acid transporters (URAT1). |
Reduces serum uric acid levels and mitigates hyperuricemia symptoms. |
|
Luteolin |
Citrus spp. (citrus fruits), Apium graveolens (celery) |
Competitive XOD inhibition with a high binding affinity (2.38 × 10−6 mol/L). |
Effective in lowering uric acid levels in clinical trials and animal studies. |
|
Isorhamnetin |
Hippophae rhamnoides (sea buckthorn) |
Inhibits hepatic XOD activity and reduces serum uric acid levels. |
Significant uric acid reduction in animal models, potential therapeutic agent. |
Phenolic Acids
|
Chlorogenic Acid |
Coffea arabica (coffee), Eugenia uniflora (surinam cherry) |
Inhibits XOD activity, reduces uric acid production, and modulates inflammatory pathways. |
Decreases serum uric acid levels and inhibits XOD activity. |
|
Caffeic Acid |
Salvia officinalis (sage), Coffea arabica (coffee) |
Down-regulates URAT1 and GLUT9, up-regulates OAT1, competitive XOD inhibition. |
Reduces uric acid levels and manages hyperuricemia through modulation |
Saponins
|
Ginsenosides |
Panax ginseng
|
Anti-inflammatory properties that may indirectly support uric acid reduction. |
Indirectly influences uric acid levels through overall health improvement. |
Alkaloids
|
Vindoline |
Vinca rosea (periwinkle) |
Broader therapeutic actions that impact metabolic pathways. |
|